Weight-Loss Injections Are Dominating the Market: The place Will GLP-1 Drugs Match In?

With the primary GLP-1 capsules for weight reduction on the horizon, GoodRx shares the place they may slot in.

Key takeaways:

• Glucagon-like peptide-1 (GLP-1) injections akin to Wegovy (semaglutide) and Zepbound (tirzepatide) are the simplest weight-loss medicines obtainable at this time.
• Oral GLP-1 capsules, akin to orforglipron, oral semaglutide, and VK2735, are in growth. The FDA might approve orforglipron and oral semaglutide by 2026.
• GLP-1 capsules could also be used as preliminary remedies or upkeep remedy after injections. They is also used as a part of a versatile step-up or step-down technique.
• Components akin to effectiveness, adherence, and affordability might affect how rapidly and broadly GLP-1 capsules are used as soon as obtainable.

What are GLP-1 medicines?

GLP-1 medicines mimic GLP-1, a hormone that helps regulate urge for food, blood glucose (blood sugar), and digestion. Most of those medicines are designed to imitate GLP-1 alone. Others, like tirzepatide, additionally mimic GIP (glucose-dependent insulinotropic polypeptide) for additive results.

At the moment, most GLP-1s are injections used to deal with Kind 2 diabetes. A couple of, together with Wegovy, Zepbound, and Saxenda (liraglutide), are FDA-approved for weight reduction. Oral semaglutide (Rybelsus) is the one capsule possibility at present obtainable. However proper now, it’s solely permitted to deal with Kind 2 diabetes.

Up to now, GLP-1 injections have been the simplest possibility for weight reduction. However newer GLP-1 capsules purpose to match, and even enhance upon, their outcomes.

Why GLP-1 capsules could possibly be a game-changer

A number of oral GLP-1 capsules are in late-stage growth — they usually’re getting nearer to hitting the market. They work in an identical method as injectable GLP-1s. However they arrive in a capsule, which could possibly be extra interesting and handy for many individuals.

Oral semaglutide is already permitted for Kind 2 diabetes at doses as much as 14 mg every day. Larger doses (25 mg, 50 mg) have been studied for weight reduction and should supply related outcomes to the Wegovy 2.4 mg dose. However it’s essential to notice that oral semaglutide isn’t absorbed in addition to the injection. You want to take it on an empty abdomen very first thing within the morning to maximise absorption.

Orforglipron is a non-peptide oral GLP-1 treatment. It’s made utilizing a less complicated manufacturing course of than GLP-1 injections. This might result in decrease costs, simpler manufacturing, and fewer provide points. And in comparison with oral semaglutide, it’s extra simply absorbed by the physique and doesn’t must be timed round meals.

VK2735 is one other treatment that mimics each GLP-1 and GIP, like tirzepatide. Early trial outcomes for oral VK2735 present promising weight-loss outcomes with manageable negative effects. It’s at present being studied in a section 2 trial to check completely different doses. Researchers are additionally finding out an injectable model, which is additional alongside within the scientific growth course of.

How GLP-1 capsules could also be used for weight reduction

Fatima Cody Stanford, MD, MPH, MPA, an weight problems drugs physician-scientist, educator, and policymaker at Massachusetts Common Hospital and Harvard Medical College, defined to GoodRx Well being how these oral choices may match into completely different therapy methods.

Preliminary weight-loss remedies

Some folks might begin their GLP-1 journey with a capsule, particularly in the event that they’re hesitant about injections. A every day oral treatment might really feel extra acquainted and simpler to handle.

“Self-injection could be a vital barrier for some folks, both because of needle phobia, inconvenience, or perceived stigma,” defined Stanford. “Oral choices may enhance their willingness to provoke and cling to therapy, probably broadening the pool of people that can profit from (GLP-1) remedy.”

Upkeep remedy after weight reduction

For individuals who’ve already misplaced weight with an injectable GLP-1, switching to a capsule might assist preserve progress with out persevering with injections.

“Oral medicines might certainly operate as an ‘off-ramp’ for many who have reached their therapy objectives with injectables and want to preserve their progress with a much less invasive possibility,” mentioned Stanford. “This transition might assist in sustaining motivation and adherence to therapy over the long run.”

This upkeep strategy is at present being investigated. The ATTAIN-MAINTAIN trial research how orforglipron helps folks hold weight off after stopping Zepbound. And oral VK2735 might play an identical position with the injectable model.

Step-up or step-down methods

GLP-1 capsules might additionally assist versatile therapy plans, relying on an individual’s wants and preferences.

One possibility is a step-up strategy, which can assist ease folks into therapy. This technique could also be particularly interesting for these hesitant to begin with injections instantly. As defined by Stanford, “Individuals may start with oral medicines to realize preliminary weight reduction or glycemic management, after which transition to injections if extra intensive therapy is required.”

On the flip facet, a step-down strategy can be utilized to simplify issues or decrease therapy depth after reaching objectives. On this case, somebody may swap from the injections to a capsule to scale back negative effects, decrease price, or make the routine simpler to stay to.

Whether or not somebody is beginning or persevering with therapy, GLP-1 capsules might give folks extra choices to assist meet or preserve their long-term physique weight objectives.

Challenges going through GLP-1 weight-loss capsules

Earlier than GLP-1 capsules go mainstream, a number of questions stay. Stanford famous elements akin to effectiveness, adherence, and affordability taking part in a task in how rapidly and broadly GLP-1 capsules are adopted as soon as obtainable.

• Can they match injectable GLP-1 outcomes? Early knowledge is encouraging. Oral semaglutide (25 mg) has proven weight-loss outcomes just like Wegovy (2.4 mg). Knowledge from orforglipron’s late-stage weight-loss trial is anticipated in 2025. Constructive outcomes from its Kind 2 diabetes trial have already been introduced.
• Will they provide the identical well being advantages? Injectable GLP-1s have proven advantages past weight reduction, together with coronary heart safety and sleep apnea enchancment. Analysis has but to substantiate if oral choices will supply these identical advantages.
• Will adherence enhance with a every day capsule? Some folks might favor a every day capsule over a weekly injection. However others may wrestle with remembering a every day dose. That is particularly the case if there are strict directions to observe when taking it.
• Will they be inexpensive and lined by insurance coverage? Drugs like orforglipron could also be simpler and cheaper to make. However pricing and insurance coverage protection stay unsure.
• Can oral choices stop future shortages? Semaglutide and tirzepatide shortages have largely resolved in 2025, however demand stays excessive. Non-peptide oral GLP-1s are typically simpler to supply. This may increasingly assist relieve strain on provide chains and assist extra constant treatment entry.

What’s subsequent for oral GLP-1 medicines?

With rising curiosity in weight-loss remedies, a number of GLP-1 capsules are shifting via scientific trials. Right here’s the place the highest candidates at present stand:

• Larger-dose semaglutide (oral Wegovy): The FDA has accepted the producer’s utility for oral Wegovy. The company is anticipated to decide in This autumn 2025.
• Orforglipron: Section 3 trial outcomes are anticipated in 2025. If the whole lot goes as deliberate, the FDA might approve orforglipron in 2026.
• VK2735: Section 2 trial outcomes for oral VK2735 are anticipated within the second half of 2025. The injectable model is advancing to section 3 trials in 2025.

The underside line

Glucagon-like peptide-1 (GLP-1) injections like Wegovy (semaglutide) and Zepbound (tirzepatide) have revolutionized the weight-loss treatment market. However oral GLP-1 capsules are on the horizon and will quickly supply a less complicated, extra versatile possibility for weight reduction.

High candidates embrace orforglipron, oral semaglutide, and VK2735. The FDA might approve orforglipron and oral semaglutide by 2026.

This story was produced by GoodRx and reviewed and distributed by Stacker.